Arrowhead Pharmaceuticals (NASDAQ: ARWR) details fiscal 2026 results

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals, Inc. filed a current report to note that it has announced and discussed its fiscal 2026 financial results for the period ended December 31, 2025. These results were shared through a press release dated February 5, 2026.

The press release is provided as Exhibit 99.1 and is designated as “furnished” rather than “filed,” which limits its use in certain legal contexts. The company also included an Inline XBRL cover page data file as Exhibit 104, signed on behalf of Arrowhead by Chief Financial Officer Daniel Apel.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000879407FALSE00008794072026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

February 5, 2026

Date of Report

(Date of earliest event reported)

Arrowhead Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38042

46-0408024

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105

(Address of principal executive offices, including Zip Code)

(626) 304-3400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ARWR

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On February 5, 2026, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2026 financial results for the period ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release, dated February 5, 2026.
104						Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 5, 2026

ARROWHEAD PHARMACEUTICALS, INC.
By:						/s/ Daniel Apel
						Daniel Apel
						Chief Financial Officer

FAQ

What did Arrowhead Pharmaceuticals (ARWR) disclose in this 8-K filing?

Arrowhead Pharmaceuticals disclosed that it announced and commented on its fiscal 2026 financial results for the period ended December 31, 2025. These details are contained in a press release furnished as Exhibit 99.1 to the report.

Which period do Arrowhead Pharmaceuticals’ fiscal 2026 results in this 8-K cover?

The fiscal 2026 results discussed in this 8-K cover the period ended December 31, 2025. Arrowhead Pharmaceuticals furnished these results through a press release, allowing investors to review performance for that specific reporting period.

How did Arrowhead Pharmaceuticals provide its fiscal 2026 financial results to investors?

Arrowhead Pharmaceuticals provided its fiscal 2026 financial results through a press release dated February 5, 2026. That press release is attached to the 8-K as Exhibit 99.1 and is treated as furnished, not filed, under securities laws.

Who signed Arrowhead Pharmaceuticals’ February 5, 2026 8-K report?

The 8-K report was signed on behalf of Arrowhead Pharmaceuticals by Daniel Apel, the company’s Chief Financial Officer. His signature confirms the company’s authorization of the disclosure about its fiscal 2026 financial results.

What exhibits are included with Arrowhead Pharmaceuticals’ 8-K on fiscal 2026 results?

The 8-K includes Exhibit 99.1, a press release dated February 5, 2026, discussing fiscal 2026 results, and Exhibit 104, an Inline XBRL cover page interactive data file embedding the cover page tags within the electronic document.